Press Releases
June 10, 2011
Revance Announces $45 Million Financing
NEWARK, Calif. - June 10, 2011 - Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital (NovaQuest). New investor, CNF Investments, also joined the syndicate which included participation from existing investors: Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. read more...
October 22, 2010
Revance Therapeutics Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society of Dermatologic Surgery
NEWARK, Calif. - October 22, 2010 - Revance Therapeutics, Inc. ("Revance") today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinim toxin type A which is under investigation for the treatment of lateral canthal lines (crow's feet wrinkles) were presented at the annual meeting of the American Society of Dermatologic Surgery in Chicago. read more...
Download press release
January 4, 2010
Revance Annouces Series D Financing
NEWARK, Calif. - January 4, 2010 - Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII. The financing included returning investors participating at their full pro rata, Essex Woodlands Fund V, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Ventures. The total Series D financing is expected reach $35 million with the participation of new investors and close in approximately ninety days. read more...
Download press release
July 28, 2009
Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin
SCOTTSDALE, Ariz. and NEWARK, Calif.-July 28, 2009-Medicis Pharmaceutical Corporation (NYSE:MRX) (Medicis) and Revance Therapeutics, Inc. (Revance) today announced that the companies have entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to Revance's novel, investigational, injectable botulinum toxin type A product (RT002) currently in pre-clinical studies. The objective of the RT002 program is the development of a next-generation neurotoxin with favorable duration of effect and safety profiles. read more...
Download press release
July 9, 2009
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. ("Revance") today announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow's feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints. read more...
Download press release
November 18, 2008
Revance Secures $8 Million in New Financing
Newark, Calif. November 18, 2008—Revance Therapeutics, Inc. (“Revance”) today
announced an agreement with Leader Ventures and Horizon Technology Finance that will
provide $8 million of venture debt financing. This financing will help Revance further the
clinical development of their lead product, RT001, a topical form botulinum toxin type A for
use in both cosmetic and therapeutic indications, and the TransMTS™ platform technology
that enables large, macromolecules to cross skin. read more...
Download press release